Cerebrovascular Department of Interventional Center, Zhengzhou University People's Hospital, Henan University People's Hospital and Henan Provincial People's Hospital, Zhengzhou, Henan, China.
Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Oxid Med Cell Longev. 2022 Jun 20;2022:9682507. doi: 10.1155/2022/9682507. eCollection 2022.
Intracranial vertebrobasilar trunk large (≥10 mm) aneurysms (IVBTLAs) are rare and challenging to manage. In this study, we describe the natural prognosis and evaluate the safety and efficacy of endovascular treatment of IVBTLAs compared with conservative therapy.
This prospective multicenter cohort study included patients with IVBTLAs, who chose either endovascular treatment (endovascular group) or conservative therapy (conservative group) after discussion with their doctors. The primary endpoint was the incidence of serious adverse events (SAEs) related to the target vessel, while secondary endpoints included target vessel-related mortality, major stroke, other serious adverse events, and aneurysm occlusion rate.
In total, 258 patients were referred to our two centers for the management of vertebrobasilar aneurysms, and 69 patients had IVBTLAs. Among them, 51 patients underwent endovascular treatment, and 18 patients received conservative therapy. The incidence of target vessel-related SAEs was 15.7% (8/51) in the endovascular group and 44.4% (8/18) in the conservative group ( = 0.031). The target vessel-related mortality was 2.0% (1/51) in the endovascular group and 38.9% (7/18) in the conservative group ( < 0.001). The cumulative survival rates in the endovascular group and conservative group within 1-year, 3-year, and 5-year were 98.0% vs. 83.3%, = 0.020; 98.0% vs. 66.7%, = 0.001; and 98.0% vs. 35.6%, < 0.001, respectively. Multivariate analysis revealed conservative therapy, giant aneurysm, and ischemic onset as risks factor for SAEs.
Compared with conservative treatment, endovascular treatment of the IVBTLAs may be associated with a lower incidence of SAEs, with higher 1-year, 3-year, and 5-year survival rates. Conservative therapy, giant aneurysm, and ischemic onset were associated with a high risk of SAEs.
颅内椎基底动脉干大(≥10mm)动脉瘤(IVBTLAs)罕见,治疗极具挑战性。本研究描述了其自然预后,并评估了血管内治疗与保守治疗相比治疗 IVBTLAs 的安全性和有效性。
本前瞻性多中心队列研究纳入了 IVBTLAs 患者,这些患者在与医生讨论后选择血管内治疗(血管内组)或保守治疗(保守组)。主要终点是与靶血管相关的严重不良事件(SAE)的发生率,次要终点包括与靶血管相关的死亡率、主要卒中、其他严重不良事件和动脉瘤闭塞率。
共有 258 例患者因椎基底动脉动脉瘤就诊于我们的两个中心,其中 69 例患者为 IVBTLAs。其中,51 例患者接受血管内治疗,18 例患者接受保守治疗。血管内组与靶血管相关 SAE 的发生率为 15.7%(8/51),保守组为 44.4%(8/18)(=0.031)。血管内组与靶血管相关的死亡率为 2.0%(1/51),保守组为 38.9%(7/18)(<0.001)。血管内组和保守组在 1 年、3 年和 5 年内的累积生存率分别为 98.0%与 83.3%,=0.020;98.0%与 66.7%,=0.001;98.0%与 35.6%,<0.001。多因素分析显示,保守治疗、巨大动脉瘤和缺血性起病是 SAE 的危险因素。
与保守治疗相比,血管内治疗 IVBTLAs 可能与较低的 SAE 发生率相关,1 年、3 年和 5 年生存率更高。保守治疗、巨大动脉瘤和缺血性起病与 SAE 风险较高相关。